CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
30 sept. 2024 19h07 HE
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
Afamelanotide in fair-skinned Parkinson’s patients
17 juin 2024 20h39 HE
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28 mars 2024 04h25 HE
|
Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
01 févr. 2023 19h14 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
CLINUVEL Trial Results Show Drug Reduces DNA Damage
15 janv. 2023 18h23 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...
CLINUVEL progresses vitiligo treatment program
09 mai 2022 21h33 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
Positive final results in stroke
03 mai 2022 20h24 HE
|
Clinuvel Pharmaceuticals Limited
ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
CLINUVEL to Trial Innovative Drug in Stroke
27 oct. 2020 18h50 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
First patient dosed in SCENESSE® DNA Repair Program
15 sept. 2020 03h31 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video...
CLINUVEL progresses innovative DNA Repair Program
10 sept. 2020 03h18 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...